1,300th Implant of the SynCardia Total Artificial Heart Was Performed in April 2014
When All Other Treatments Fail, the SynCardia Total Artificial Heart Can Save the Sickest of the Sick. The Freedom Portable Driver Allows a Majority of SynCardia Patients to be Discharged from the Hospital to Live at Home & Get In Better Shape for Their Heart Transplant.
TUCSON, Ariz. – May 20, 2014 – SynCardia Systems, Inc. announced today that a United States patient with end-stage biventricular heart failure received the 1,300th implant of the SynCardia temporary Total Artificial Heart as a bridge to transplant in April 2014.
“The SynCardia Heart saves patients dying of end-stage biventricular (both sides) heart failure and the Freedom® portable driver provides patients without human hearts a life worth living outside the hospital,” says Michael P. Garippa, SynCardia CEO and President. “Discharge on the 13.5-pound Freedom portable driver improves the patient’s quality of life with nearly unlimited mobility while eliminating most in-hospital costs for this portion of their care.”
According to the New England Journal of Medicine (N Engl J Med 2004;351:859-67), Total Artificial Heart patients have the highest bridge to transplant rate of any approved device, 79%. During the last 24 months there have been over 300 implants of the SynCardia Heart.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces the two failing ventricles and four heart valves. It is the only device that eliminates the source and symptoms of end-stage heart failure.
Over 175 patients have been supported by the Freedom® portable driver totalling over 100 years of support.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles no longer can pump enough blood for the patient to survive.
The SynCardia Heart has been used to address multiple heart failure etiologies that may lead to end-stage biventricular failure, including cardiac tumor, ventricular septal defect, LVAD (left ventricular assist device) failure, heart transplant failure, arrhythmias and heart attack.
About the SynCardia temporary Total Artificial Heart
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463